[go: up one dir, main page]

MX2014006594A - Compuestos de enzimas lisosomales apuntados. - Google Patents

Compuestos de enzimas lisosomales apuntados.

Info

Publication number
MX2014006594A
MX2014006594A MX2014006594A MX2014006594A MX2014006594A MX 2014006594 A MX2014006594 A MX 2014006594A MX 2014006594 A MX2014006594 A MX 2014006594A MX 2014006594 A MX2014006594 A MX 2014006594A MX 2014006594 A MX2014006594 A MX 2014006594A
Authority
MX
Mexico
Prior art keywords
compounds
lysosomal enzyme
compound
targeting moiety
enzyme compounds
Prior art date
Application number
MX2014006594A
Other languages
English (en)
Inventor
Dominique Boivin
Jean-Paul Castaigne
Michel Demeule
Sasmita Tripathy
Jean-Christophe Currie
Simon Lord-Dufour
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of MX2014006594A publication Critical patent/MX2014006594A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está relacionada con un compuesto que incluye un enzima lisosomal y una fracción que apunta, por ejemplo, donde el compuesto es una proteína de fusión que incluye una 2-sulfatasa iduronato y Angiopep-2. En ciertas formas de realización, estos compuestos, debido a la presencia de la fracción que apunta, pueden cruzar la barrera hematoencefálica o acumularse en el lisosoma de manera más efectiva que la enzima sola. La invención también se refiere a métodos para tratar desórdenes del almacenamiento lisosomal (v. gr., mucopolisacarido-sis tipo II) usando tales compuestos.
MX2014006594A 2011-12-01 2012-11-30 Compuestos de enzimas lisosomales apuntados. MX2014006594A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161565764P 2011-12-01 2011-12-01
US201261596515P 2012-02-08 2012-02-08
US201261660564P 2012-06-15 2012-06-15
PCT/CA2012/050867 WO2013078564A2 (en) 2011-12-01 2012-11-30 Targeted lysosomal enzyme compounds

Publications (1)

Publication Number Publication Date
MX2014006594A true MX2014006594A (es) 2015-09-16

Family

ID=48536183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006594A MX2014006594A (es) 2011-12-01 2012-11-30 Compuestos de enzimas lisosomales apuntados.

Country Status (11)

Country Link
US (1) US20150037311A1 (es)
EP (1) EP2785838A4 (es)
JP (1) JP2015505824A (es)
CN (1) CN104145015A (es)
AU (1) AU2012344702A1 (es)
BR (1) BR112014013161A2 (es)
CA (1) CA2857567A1 (es)
HK (2) HK1204002A1 (es)
MX (1) MX2014006594A (es)
RU (1) RU2014126484A (es)
WO (1) WO2013078564A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2260874A1 (en) 2003-01-06 2010-12-15 Angiochem Inc. Aprotinin analogs as carriers across the blood-brain barrier
JP5436856B2 (ja) 2005-07-15 2014-03-05 アンジオケム インコーポレーティッド 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
DK2279008T3 (en) 2008-04-18 2019-04-29 Angiochem Inc PHARMACEUTICAL COMPOSITIONS OF PACLITAXEL, PACLITAXEL ANALOGS OR PACLITAXEL CONJUGATES AND RELATED PROCEDURES FOR PREPARATION AND USE
CN102245642A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 Glp-1激动剂的结合物及其用途
JP5705118B2 (ja) 2008-10-15 2015-04-22 アンジオケム インコーポレーテッド 薬物送達のためのエトポシドおよびドキソルビシン複合体
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
CA2747220A1 (en) 2008-12-17 2010-06-24 Richard Beliveau Membrane type-1 matrix metalloprotein inhibitors and uses thereof
CN102510759A (zh) 2009-04-20 2012-06-20 安吉奥开米公司 利用与血管肽-2类似物结合的抗癌剂治疗卵巢癌
JP5932642B2 (ja) 2009-07-02 2016-06-08 アンジオケム インコーポレーテッド 多量体ペプチドコンジュゲートおよびその使用
CA2876525A1 (en) * 2012-06-15 2013-12-19 Angiochem Inc. Targeted iduromdase compounds
AU2013302270A1 (en) 2012-08-14 2015-03-26 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
HK1215049A1 (zh) 2013-03-15 2016-08-12 阿米库斯治疗学公司 化學交聯劑
WO2014194428A1 (en) * 2013-06-06 2014-12-11 Angiochem Inc. Targeted heparan sulfatase compounds
EP3613755A1 (en) 2013-07-11 2020-02-26 Novartis AG Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
JP6675333B2 (ja) * 2014-06-23 2020-04-01 ノバルティス アーゲー 部位特異的タンパク質修飾
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
WO2021207273A1 (en) * 2020-04-07 2021-10-14 The Regents Of The University Of California Manufacturing of synthetic exosomes for cns and non-cns delivery of therapeutics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463473A1 (en) * 2001-10-16 2003-04-24 Symbiontics Inc. Targeted therapeutic proteins
CA2487815A1 (en) * 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
WO2004108071A2 (en) * 2003-06-05 2004-12-16 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
PL1877099T3 (pl) * 2005-04-06 2013-02-28 Genzyme Corp Terapeutyczne koniugaty zawierające enzym lizosomalny, kwas polisialowy i grupę kierującą
EP2235175A4 (en) * 2007-12-20 2012-04-25 Angiochem Inc POLYPEPTIDE-NUCLEIC ACID CONJUGATES AND USES THEREOF
RU2011125366A (ru) * 2008-12-05 2013-01-10 Ангиочем Инк. Конъюгаты терапевтических пептидов и их применение
WO2010063122A1 (en) * 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
WO2011041897A1 (en) * 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
BR112014013250A2 (pt) * 2011-12-01 2019-09-24 Angiochem Inc compostos com enzima alvo e usos dos mesmos

Also Published As

Publication number Publication date
HK1204002A1 (en) 2015-11-06
EP2785838A2 (en) 2014-10-08
BR112014013161A2 (pt) 2019-09-24
WO2013078564A2 (en) 2013-06-06
RU2014126484A (ru) 2016-02-10
CA2857567A1 (en) 2013-06-06
WO2013078564A3 (en) 2013-09-06
AU2012344702A1 (en) 2014-06-19
HK1200189A1 (en) 2015-07-31
US20150037311A1 (en) 2015-02-05
JP2015505824A (ja) 2015-02-26
EP2785838A4 (en) 2015-07-01
CN104145015A (zh) 2014-11-12

Similar Documents

Publication Publication Date Title
MX2014006594A (es) Compuestos de enzimas lisosomales apuntados.
WO2013078562A3 (en) Targeted iduronate-2-sulfatase compounds
MX2014015551A (es) Compuestos iduronidasa apuntados.
PH12020550510A1 (en) Fusion proteins comprising enzyme replacement therapy enzymes
WO2010148253A3 (en) Formulations for lysosomal enzymes
PH12019550261A1 (en) Compositions and methods for internalizing enzymes
MA35023B1 (fr) Inhibiteurs de la glucosylcéramide synthase
PH12018501074A1 (en) Compositions and methods for internalizing enzymes
MX367024B (es) Proteinas de fusion de enzima lisosomal terapeutica objetivo y usos de las mismas.
BR112012033197A2 (pt) métodos e composições para liberação de cns de n-sulfatase de heparano.
EA201291107A1 (ru) Соединения, ингибирующие металлоферменты
EA201490052A1 (ru) Соединения, ингибирующие металлоферменты
EA201490036A1 (ru) Соединения, ингибирующие металлоферменты
TN2012000280A1 (en) Methods of administering pirfenidone therapy
MX347808B (es) Variantes de plasminogeno y plasmina.
AU2011270668A8 (en) CNS delivery of therapeutic agents
IN2014CN02584A (es)
MX337248B (es) Variantes de plasminogeno y plasmina.
WO2013026740A3 (en) Methods and means to modify a plant genome
WO2011163652A3 (en) Treatment of sanfilippo syndrome type b
MX2013000321A (es) Suministro al sistema nervioso central de agentes terapeuticos.
BR112014013963A8 (pt) compostos inibidores de metaloenzimas
WO2013091897A8 (en) Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
WO2011087548A3 (en) Therapeutic compositions and methods for targeted delivery of active agents
WO2013119946A8 (en) Long chain base sphingosine kinase inhibitors